SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Phil Cressman who wrote (29238)9/2/1999 10:02:00 AM
From: Henry Niman  Respond to of 32384
 
My guess is WLA got LGND very cheap, which is why price wasn't in press release. However, I believe that LGND was talking SERMs to WLA quite some time ago (9-12 months ago), so price might not be quite as bad as LGND's current price.



To: Phil Cressman who wrote (29238)9/2/1999 10:31:00 AM
From: Henry Niman  Respond to of 32384
 
I suspect that LGND has to be near the top of the list with Pharma partners (PFE, AGN, GLX, ABT, AHP, SBH, Sankyo, LLY, WLA), but they must have a huge lead on selling a single program, SERMs.

They have now done deals with PFE, AHP, LLY, and WLA and have 4 SERM products (Droloxifene, CP-366,156, TSE-424, ERA-923) in the clinic!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News